527 related articles for article (PubMed ID: 33117358)
1. Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy.
Steingold JM; Hatfield SM
Front Immunol; 2020; 11():570041. PubMed ID: 33117358
[TBL] [Abstract][Full Text] [Related]
2. Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.
Sitkovsky MV; Hatfield S; Abbott R; Belikoff B; Lukashev D; Ohta A
Cancer Immunol Res; 2014 Jul; 2(7):598-605. PubMed ID: 24990240
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic Justifications of Systemic Therapeutic Oxygenation of Tumors to Weaken the Hypoxia Inducible Factor 1α-Mediated Immunosuppression.
Hatfield S; Veszeleiova K; Steingold J; Sethuraman J; Sitkovsky M
Adv Exp Med Biol; 2019; 1136():113-121. PubMed ID: 31201720
[TBL] [Abstract][Full Text] [Related]
4. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.
Hatfield SM; Sitkovsky M
Curr Opin Pharmacol; 2016 Aug; 29():90-6. PubMed ID: 27429212
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia.
Sitkovsky MV; Kjaergaard J; Lukashev D; Ohta A
Clin Cancer Res; 2008 Oct; 14(19):5947-52. PubMed ID: 18829471
[TBL] [Abstract][Full Text] [Related]
6. Oxygenation and A2AR blockade to eliminate hypoxia/HIF-1α-adenosinergic immunosuppressive axis and improve cancer immunotherapy.
Halpin-Veszeleiova K; Hatfield SM
Curr Opin Pharmacol; 2020 Aug; 53():84-90. PubMed ID: 32841869
[TBL] [Abstract][Full Text] [Related]
7. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
8. NF-κB enhances hypoxia-driven T-cell immunosuppression via upregulation of adenosine A(2A) receptors.
Bruzzese L; Fromonot J; By Y; Durand-Gorde JM; Condo J; Kipson N; Guieu R; Fenouillet E; Ruf J
Cell Signal; 2014 May; 26(5):1060-7. PubMed ID: 24486403
[TBL] [Abstract][Full Text] [Related]
9. A
Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
[TBL] [Abstract][Full Text] [Related]
10. Targeting adenosine for cancer immunotherapy.
Leone RD; Emens LA
J Immunother Cancer; 2018 Jun; 6(1):57. PubMed ID: 29914571
[TBL] [Abstract][Full Text] [Related]
11. Sufficient numbers of anti-tumor T cells is a condition of maximal efficacy of anti-hypoxia-A2-adenosinergic drugs during cancer immunotherapy.
Sitkovsky MV
Curr Opin Pharmacol; 2020 Aug; 53():98-100. PubMed ID: 32861959
[TBL] [Abstract][Full Text] [Related]
12. Adenosine A
Atif M; Alsrhani A; Naz F; Ullah MI; Alameen AAM; Imran M; Ejaz H
Mol Biol Rep; 2022 Nov; 49(11):10677-10687. PubMed ID: 35752699
[TBL] [Abstract][Full Text] [Related]
13. A2A adenosine receptor protects tumors from antitumor T cells.
Ohta A; Gorelik E; Prasad SJ; Ronchese F; Lukashev D; Wong MK; Huang X; Caldwell S; Liu K; Smith P; Chen JF; Jackson EK; Apasov S; Abrams S; Sitkovsky M
Proc Natl Acad Sci U S A; 2006 Aug; 103(35):13132-7. PubMed ID: 16916931
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy.
Kurago Z; Guo G; Shi H; Bollag RJ; Groves MW; Byrd JK; Cui Y
Front Immunol; 2023; 14():1212209. PubMed ID: 37435071
[TBL] [Abstract][Full Text] [Related]
15. Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
Vigano S; Alatzoglou D; Irving M; Ménétrier-Caux C; Caux C; Romero P; Coukos G
Front Immunol; 2019; 10():925. PubMed ID: 31244820
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.
Kamai T; Kijima T; Tsuzuki T; Nukui A; Abe H; Arai K; Yoshida KI
Cancer Immunol Immunother; 2021 Jul; 70(7):2009-2021. PubMed ID: 33416945
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.
Giuffrida L; Sek K; Henderson MA; Lai J; Chen AXY; Meyran D; Todd KL; Petley EV; Mardiana S; Mølck C; Stewart GD; Solomon BJ; Parish IA; Neeson PJ; Harrison SJ; Kats LM; House IG; Darcy PK; Beavis PA
Nat Commun; 2021 May; 12(1):3236. PubMed ID: 34050151
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
19. CD39/CD73/A2AR pathway and cancer immunotherapy.
Xia C; Yin S; To KKW; Fu L
Mol Cancer; 2023 Mar; 22(1):44. PubMed ID: 36859386
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro.
Fallah-Mehrjardi K; Mirzaei HR; Masoumi E; Jafarzadeh L; Rostamian H; Khakpoor-Koosheh M; Alishah K; Noorbakhsh F; Hadjati J
Immunol Lett; 2020 Jul; 223():44-52. PubMed ID: 32289340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
